(Q24794927)

English

The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

scientific article

In more languages

Statements

scholarly article

0 references

1 reference

26 August 2020

The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer (English)

0 references

ubiquitin-proteasome system

1 reference

based on heuristic

inferred from abstract

breast neoplasm

1 reference

26 August 2020

cysteine endopeptidases

1 reference

28 September 2019

multienzyme complex

1 reference

16 November 2019

1 reference

22 December 2019

protein ubiquitination

1 reference

based on heuristic

inferred from title

signal transduction

1 reference

26 August 2020

1 reference

based on heuristic

inferred from title

Robert Z Orlowski

1

object named as

Robert Z Orlowski

0 references

2

object named as

E Claire Dees

0 references

language of work or name

0 references

publication date

2003

0 references

14 August 2002

7 references

13 March 2019

3 April 2019

17 June 2019

28 September 2019

16 November 2019

22 December 2019

26 August 2020

Breast Cancer Research

7 references

13 March 2019

3 April 2019

17 June 2019

28 September 2019

16 November 2019

22 December 2019

26 August 2020

5

0 references

1

0 references

1-7

0 references

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

Proteasomes are a target of the anti-tumour drug vinblastine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

Rapamycin inhibits proteasome activator expression and proteasome activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

7 April 2017

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

NF-kappaB as a therapeutic target in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Deadly encounter: ubiquitin meets apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Identification of apoptotic cells by formamide-induced dna denaturation in condensed chromatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Common pathway for the ubiquitination of IkappaBalpha, IkappaBbeta, and IkappaBepsilon mediated by the F-box protein FWD1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

The role of the ubiquitin-proteasome pathway in apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Growth factors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 September 2017

Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

30 May 2018

p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

The human 26S proteasome is a target of antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome.

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway

1 reference

https://api.crossref.org/works/10.1186%2FBCR460

21 January 2018

Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 November 2018

Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 November 2018

Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 November 2018

The proteasome inhibitor PS-341 in cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=154126

28 November 2018

Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12559038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12559038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abnormal expression of MDM-2 in breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12559038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12559038

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24794927&oldid=2175254341"